

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天 安 卓 健 有 限 公 司

TIAN AN MEDICARE LIMITED

(Incorporated in Bermuda with limited liability)

(Stock Code: 383)

POSITIVE PROFIT ALERT

This announcement is made by Tian An Medicare Limited (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on its preliminary review on the relevant unaudited consolidated management accounts of the Group for the five months ended 31 May 2024 and information currently available, subject to any impairment adjustment(s), fair value change and/or provision adjustment(s) on properties or other adjustment(s), the Group is expected to record an unaudited profit attributable to Shareholders in the estimated range of approximately HK\$15 million to HK\$45 million for the five months ended 31 May 2024 as compared with (a) the loss for the corresponding period in 2023; and (b) the loss of approximately HK\$2 million for the six months ended 30 June 2023. This was mainly due to (i) the increase in revenue from operations of the healthcare division following the relaxation of epidemic preventive measures and the resumption of economic and social activities in the Peoples’ Republic of China (the “**PRC**”); (ii) the decrease in cost of medical consumables; (iii) the increase in interest income from bank deposits; and (iv) the decrease in finance costs of borrowings in the PRC but were partially off-set by (v) the increase in cost of pharmaceutical and medicine.

This announcement is only based on the preliminary review on the relevant unaudited consolidated management accounts of the Group for the five months ended 31 May 2024 and information currently available, which have not been confirmed or reviewed by the auditor nor reviewed by the audit committee of the Company, and therefore is subject to adjustments where necessary. The Company expects to announce its unaudited interim results for the six months ended 30 June 2024 in August 2024. Further announcement(s) will be made by the Company as and when appropriate.

Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By Order of the Board
Tian An Medicare Limited
Kong Muk Yin
Executive Director

Hong Kong, 9 July 2024

As at the date of this announcement, the Board comprises Mr. Kong Muk Yin, Mr. Guo Meibao and Mr. Zhou Haiying being Executive Directors; Mr. Lee Seng Hui (Chairman), Mr. Mark Wong Tai Chun and Mr. Gao Zhaoyuan being Non-Executive Directors; and Mr. Zhang Jian, Dr. Xia Xiaoning, Dr. Wong Wing Kuen, Albert and Ms. Yang Lai Sum, Lisa being Independent Non-Executive Directors.